Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Smurfit Kappa GP Director's Dealing 2018

Jun 11, 2018

1952_rns_2018-06-11_7fd51158-ce91-4b9d-9535-d1f4769455d7.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0071R

Northern Trust Corporation

11 June 2018

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) Northern Trust Group
Company dealt in International Paper Company
Class of relevant security to which the dealings being disclosed relate (Note 2) USD1.00 common stock
Date of dealing 08th  June 2018

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%) Number (%)
(1) Relevant securities 4,961,278     1.20%
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total 4,961,278     1.20%

* Note: The difference in holdings from yesterday and today not explained by transactions, can be explained by stock transfers of 1,164 securities out of the relevant accounts

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale Number of relevant securities Price per unit ($)
BUY 8 58.46
BUY 85 58.59
BUY 13 58.81
BUY 22 58.8907
BUY 4 58.8907
BUY 4 58.8907
BUY 84 58.85
BUY 62 58.81
BUY 5 58.8907
BUY 5 58.8907
BUY 8 58.8907
BUY 33 58.84
BUY 29 58.8907
BUY 19 58.8907
BUY 18 58.8907
SELL 200 58.82

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit

(Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure 11th  June 2018
Contact name Alexandra Marshall-Grant
Telephone number 020 7982 1844
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISEEADKFFDXPEFF